Occidental Asset Management LLC Buys 250 Shares of Eli Lilly and Company (NYSE:LLY)

Occidental Asset Management LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 15.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,833 shares of the company’s stock after purchasing an additional 250 shares during the period. Occidental Asset Management LLC’s holdings in Eli Lilly and Company were worth $860,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Oxler Private Wealth LLC grew its holdings in shares of Eli Lilly and Company by 0.4% in the first quarter. Oxler Private Wealth LLC now owns 6,050 shares of the company’s stock worth $2,078,000 after purchasing an additional 24 shares during the last quarter. Missouri Trust & Investment Co lifted its stake in Eli Lilly and Company by 3.2% in the first quarter. Missouri Trust & Investment Co now owns 774 shares of the company’s stock worth $266,000 after acquiring an additional 24 shares during the period. Silvercrest Asset Management Group LLC lifted its stake in Eli Lilly and Company by 0.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 4,331 shares of the company’s stock worth $1,487,000 after acquiring an additional 25 shares during the period. Cora Capital Advisors LLC lifted its stake in Eli Lilly and Company by 2.8% in the first quarter. Cora Capital Advisors LLC now owns 956 shares of the company’s stock worth $328,000 after acquiring an additional 26 shares during the period. Finally, Sittner & Nelson LLC lifted its stake in Eli Lilly and Company by 2.7% in the first quarter. Sittner & Nelson LLC now owns 1,003 shares of the company’s stock worth $344,000 after acquiring an additional 26 shares during the period. 81.38% of the stock is currently owned by institutional investors.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $571.17 on Tuesday. The company’s fifty day moving average price is $512.56 and its 200 day moving average price is $439.28. Eli Lilly and Company has a 1 year low of $296.32 and a 1 year high of $601.84. The stock has a market capitalization of $542.21 billion, a P/E ratio of 79.44, a P/E/G ratio of 2.37 and a beta of 0.32. The company has a debt-to-equity ratio of 1.63, a quick ratio of 0.87 and a current ratio of 1.13.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.98 by $0.13. The company had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a return on equity of 65.00% and a net margin of 22.01%. The firm’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.25 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 9.84 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th were issued a $1.13 dividend. The ex-dividend date was Monday, August 14th. This represents a $4.52 dividend on an annualized basis and a yield of 0.79%. Eli Lilly and Company’s payout ratio is currently 62.87%.

Analysts Set New Price Targets

A number of analysts recently weighed in on LLY shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $630.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, September 5th. StockNews.com started coverage on shares of Eli Lilly and Company in a research note on Thursday, August 17th. They issued a “buy” rating for the company. Truist Financial upped their price objective on shares of Eli Lilly and Company from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Barclays increased their price target on shares of Eli Lilly and Company from $500.00 to $590.00 and gave the company an “overweight” rating in a research report on Wednesday, August 9th. Finally, Bank of America increased their price target on shares of Eli Lilly and Company from $500.00 to $600.00 in a research report on Wednesday, August 9th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty have issued a buy rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $532.78.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CAO Donald A. Zakrowski sold 600 shares of Eli Lilly and Company stock in a transaction on Monday, August 21st. The stock was sold at an average price of $546.51, for a total transaction of $327,906.00. Following the transaction, the chief accounting officer now owns 5,378 shares in the company, valued at approximately $2,939,130.78. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 11,760 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The stock was sold at an average price of $465.41, for a total value of $5,473,221.60. Following the sale, the insider now directly owns 101,237,050 shares of the company’s stock, valued at $47,116,735,440.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 976,153 shares of company stock worth $21,080,192,113. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.